Epoetin alpha helps prevent anaemia in chemotherapy patients
Author Information
Author(s): Thatcher N, Campos E S De, Bell D R, Steward W P, Varghese G, Morant R, Vansteenkiste J F, Rosso R, Ewers S-B, Sundal E, Schatzmann E, Stocker H
Primary Institution: CRC Department of Oncology, Christie Hospital NHS Trust, Manchester, UK
Hypothesis
Can epoetin α prevent the decline in haemoglobin levels and reduce transfusion requirements in patients undergoing chemotherapy for small cell lung cancer?
Conclusion
Epoetin α is effective and well-tolerated in maintaining haemoglobin levels and reducing transfusion requirements in patients undergoing chemotherapy for small cell lung cancer.
Supporting Evidence
- Epoetin α-treated patients experienced significantly less anaemia compared to untreated patients.
- Only 20% of patients receiving 300 IU/kg of epoetin α required transfusions, compared to 59% of untreated patients.
- Epoetin α was well-tolerated with no significant hypertension observed.
Takeaway
Epoetin α helps keep blood levels normal and reduces the need for blood transfusions in cancer patients getting chemotherapy.
Methodology
This multicentre study randomized 130 non-anaemic SCLC patients to receive either no treatment, epoetin α 150 IU/kg, or 300 IU/kg subcutaneously three times a week.
Participant Demographics
Non-anaemic patients undergoing chemotherapy for small cell lung cancer.
Statistical Information
P-Value
p<0.001 for 300 IU/kg; p<0.05 for 150 IU/kg
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website